Saphnelo (anifrolumab-fnia) - AstraZeneca
An Interferon-Independent Stromal-Humoral Niche Persists Following Anifrolumab Therapy in Cutaneous Lupus Erythematosus (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2834; Pres time: Nov 10, 2026; 08:15 AM - 08:30 AM; Location: W414; In Person; "While anifrolumab effectively suppresses IFN-driven inflammation in CLE, persistent plasma cells within CCL19⁺BAFF⁺ fibroblast niches reveal an IFN-independent mechanism of treatment resistance. Functional studies implicate LTα-driven non-canonical NF-κB signaling in maintaining these stromal-humoral survival niches, supporting combination strategies to achieve durable remission in refractory CLE." 
Stroma • Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • CCL19 • CXCL10 • IFNAR1 • IFNB1 • IFNG • TNFA
https://eppro02.ativ.me/web/page.php?page=session&project=ACR26&id=3564299
 
Ksenia Anufrieva1; Rochelle Castillo2; Ce Gao3; Sean Prell4; Jessica Liu5; Katharina Shaw6; Ruth Ann Vleugels7; Kevin Wei8
 
Sep 8, 2026
 
Prev Next